Rivus Pharmaceuticals

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Rivus Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).

10 total trials 1 currently recruiting 8 completed early-phase tilt top decile by trial count

Rivus Pharmaceuticals: 10 sponsored US clinical trials, 1 recruiting.

Rivus Pharmaceuticals sponsors 10 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 8 completed. 0 of these trials are in Phase 3-4 (later-stage) and 10 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Nonalcoholic Steatohepatitis, with 1 trials.

Top-decile sponsor footprint

Rivus Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

10 total, page 1 of 1

RECRUITING Phase 2

A Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH)

NCT07491458
ACTIVE NOT RECRUITING Phase 2

Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis

NCT05979779
COMPLETED Phase 1

Phase 1, Open-Label, Randomized, Study of the Safety and Pharmacokinetics of HU6

NCT07170189
COMPLETED Phase 1

Relative Bioavailability Study of HU6

NCT06486558
COMPLETED Phase 1

A Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-HU6

NCT06325930
COMPLETED Phase 2

Exploratory Ph 2A, Double-Blind, Placebo-Controlled Dose Escalation Study of Safety, Tolerability, PD, & PK of HU6 for Subjects With Obese HFpEF

NCT05284617
COMPLETED Phase 1

Safety and Pharmacokinetics of HU6

NCT05433506
COMPLETED Phase 2

Phase 2a Study of HU6 in Subjects With Elevated Liver Fat and High BMI Volunteers

NCT04874233
COMPLETED Phase 1

Multiple Ascending Dose Study of HU6 in High BMI Volunteers

NCT04709913
COMPLETED Phase 1

Ascending Dose Study of HU6 in Healthy Volunteers

NCT04463017

Phase Distribution

PhaseTrial count
Phase 1 6
Phase 2 4

Therapeutic Areas

Nonalcoholic Steatohepatitis 1
NASH - Nonalcoholic Steatohepatitis 1
Fatty Liver 1
Non-alcoholic Fatty Liver Disease 1

What is open in the Rivus Pharmaceuticals pipeline

1 recruiting of 10 indexed (10% open); 8 completed (80%).

Phase mix: 0 late (III/IV) vs 10 early (I/II) (early-phase heavy).

Top condition: Nonalcoholic Steatohepatitis (1 trial), 3 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Rivus Pharmaceuticals: open-pipeline peers nationwide

Peers matched on 10 registered trials and 10% open enrollment, not the therapeutic-area sidebar.

Rivus Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 510152025 0%10%20%30%40% Total trials Recruiting share Rivus PharmaceuticalsAdamas PharmaceuticalsAdverum BiotechnologiesAevi Genomic Medicine, LLC, a Cerecor companyAgouron PharmaceuticalsAbiomedAimmune TherapeuticsAltria Client ServicesAlzheimer's Disease Cooperative Study (ADCS)
Rivus Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Rivus Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 10 trials (± recruiting share)

Sponsors near 10% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Rivus Pharmaceuticals page

10 registered trials is a research-attention snapshot, not an endorsement of Rivus Pharmaceuticals or any single study.

  • 1 of Rivus Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Nonalcoholic Steatohepatitis is the condition Rivus Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Nonalcoholic Steatohepatitis trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Rivus Pharmaceuticals pipeline card: 10 registered trials from official public datasets.Report a data error.